Patient, cord blood, and transplant characteristics of 963 patients with hematologic malignancies undergoing dUCBT
| Characteristics . | Number of allele-level HLA mismatches∗ . | P value . | ||
|---|---|---|---|---|
| 0-3 MM N = 392 . | ≥4 MM N = 571 . | Total N = 963 . | ||
| Male, n (%) | 223 (57) | 332 (58) | 555 (58) | .70 |
| Median age, y (interquartile range) | 51 (37-60) | 48 (33-59) | 49 (34-60) | .06 |
| Median weight, kg (interquartile range) | 73 (63-83) | 72 (62-82) | 72 (62-83) | .49 |
| Positive cytomegalovirus serology, n (%) | 220 (58) | 317 (58) | 537 (58) | .98 |
| Not reported | 15 | 27 | 42 | |
| Disease type, n (%) | .54 | |||
| Acute leukemia | 251 (64) | 340 (59) | 591 (61) | |
| Lymphoma | 66 (17) | 106 (19) | 172 (18) | |
| Myelodysplastic syndrome | 32 (8) | 52 (9) | 84 (9) | |
| Myeloproliferative disorder | 26 (7) | 38 (7) | 64 (7) | |
| Others† | 17 (4) | 35 (6) | 52 (5) | |
| Disease risk index, n (%) | .10 | |||
| Low | 41 (12) | 61 (12) | 102 (12) | |
| Intermediate | 261 (74) | 344 (68) | 605 (70) | |
| High | 42 (12) | 92 (18) | 134 (16) | |
| Very high | 7 (2) | 10 (2) | 17 (2) | |
| Not reported | 41 | 64 | 105 | |
| Median cryopreserved cells, (interquartile range) | ||||
| Total nucleated cells (107/kg) ‡ | 5.0 (4.4-5.9) | 5.2 (4.4-6.1) | 5.1 (4.4-6.0) | .20 |
| Total CD34+ cells (105/kg) § | 1.9 (1.4-2.7) | 2.0 (1.5-2.8) | 2.0 (1.4-2.8) | .14 |
| Conditioning intensity, n (%) | ||||
| Myeloablative conditioning | 106 (28) | 190 (34) | 296 (32) | .05 |
| Reduced intensity conditioning | 270 (72) | 366 (66) | 636 (68) | |
| Not reported | 16 | 15 | 31 | |
| Conditioning regimens, n (%) | ||||
| CY + fludarabine + TBI (low dose) | 230 (62) | 291 (54) | 521 (57) | .05 |
| CY + fludarabine + TBI (high dose) | 56 (15) | 95 (18) | 151 (16) | |
| CY + TBI (high dose) | 16 (4) | 19 (3) | 35 (4) | |
| Others | 70 (19) | 137 (25) | 207 (23) | |
| Not reported | 20 | 29 | 49 | |
| Use of ATG, n (%) | .61 | |||
| Yes | 55 (21) | 97 (23) | 152 (24) | |
| Not reported | 129 | 141 | 270 | |
| ABO compatibility, n (%)‖ | .85 | |||
| Compatible | 66 (20) | 91 (18) | 157 (19) | |
| Minor incompatibility | 100 (30) | 149 (30) | 249 (30) | |
| Major incompatibility | 168 (50) | 258 (52) | 426 (51) | |
| Not reported | 58 | 73 | 131 | |
| Year of transplant, n (%) | .009 | |||
| ≥2012 | 225 (57) | 279 (49) | 504 (52) | |
| Median follow-up time, y | 5.1 | 5.5 | 5.2 | — |
| Characteristics . | Number of allele-level HLA mismatches∗ . | P value . | ||
|---|---|---|---|---|
| 0-3 MM N = 392 . | ≥4 MM N = 571 . | Total N = 963 . | ||
| Male, n (%) | 223 (57) | 332 (58) | 555 (58) | .70 |
| Median age, y (interquartile range) | 51 (37-60) | 48 (33-59) | 49 (34-60) | .06 |
| Median weight, kg (interquartile range) | 73 (63-83) | 72 (62-82) | 72 (62-83) | .49 |
| Positive cytomegalovirus serology, n (%) | 220 (58) | 317 (58) | 537 (58) | .98 |
| Not reported | 15 | 27 | 42 | |
| Disease type, n (%) | .54 | |||
| Acute leukemia | 251 (64) | 340 (59) | 591 (61) | |
| Lymphoma | 66 (17) | 106 (19) | 172 (18) | |
| Myelodysplastic syndrome | 32 (8) | 52 (9) | 84 (9) | |
| Myeloproliferative disorder | 26 (7) | 38 (7) | 64 (7) | |
| Others† | 17 (4) | 35 (6) | 52 (5) | |
| Disease risk index, n (%) | .10 | |||
| Low | 41 (12) | 61 (12) | 102 (12) | |
| Intermediate | 261 (74) | 344 (68) | 605 (70) | |
| High | 42 (12) | 92 (18) | 134 (16) | |
| Very high | 7 (2) | 10 (2) | 17 (2) | |
| Not reported | 41 | 64 | 105 | |
| Median cryopreserved cells, (interquartile range) | ||||
| Total nucleated cells (107/kg) ‡ | 5.0 (4.4-5.9) | 5.2 (4.4-6.1) | 5.1 (4.4-6.0) | .20 |
| Total CD34+ cells (105/kg) § | 1.9 (1.4-2.7) | 2.0 (1.5-2.8) | 2.0 (1.4-2.8) | .14 |
| Conditioning intensity, n (%) | ||||
| Myeloablative conditioning | 106 (28) | 190 (34) | 296 (32) | .05 |
| Reduced intensity conditioning | 270 (72) | 366 (66) | 636 (68) | |
| Not reported | 16 | 15 | 31 | |
| Conditioning regimens, n (%) | ||||
| CY + fludarabine + TBI (low dose) | 230 (62) | 291 (54) | 521 (57) | .05 |
| CY + fludarabine + TBI (high dose) | 56 (15) | 95 (18) | 151 (16) | |
| CY + TBI (high dose) | 16 (4) | 19 (3) | 35 (4) | |
| Others | 70 (19) | 137 (25) | 207 (23) | |
| Not reported | 20 | 29 | 49 | |
| Use of ATG, n (%) | .61 | |||
| Yes | 55 (21) | 97 (23) | 152 (24) | |
| Not reported | 129 | 141 | 270 | |
| ABO compatibility, n (%)‖ | .85 | |||
| Compatible | 66 (20) | 91 (18) | 157 (19) | |
| Minor incompatibility | 100 (30) | 149 (30) | 249 (30) | |
| Major incompatibility | 168 (50) | 258 (52) | 426 (51) | |
| Not reported | 58 | 73 | 131 | |
| Year of transplant, n (%) | .009 | |||
| ≥2012 | 225 (57) | 279 (49) | 504 (52) | |
| Median follow-up time, y | 5.1 | 5.5 | 5.2 | — |
CY, cyclophosphamide; TBI, total body irradiation.
HLA-A, -B, -C, and -DRB1 at high-resolution level. CBU with the highest HLA disparity in relation to the patient. Patients receiving at least 1 CBU with ≥5 mismatches were included even if the allele-level HLA match of the second was unknown. Bold P values denotes statistical significance (P <.05).
Plasma cell and myelodysplastic/myeloproliferative disorders.
Information was missing for 179 cases.
Information was missing for 257 cases.
CBU with the highest ABO disparity in relation to the patient.